Myelodysplastic Syndromes — Higher-Risk (IPSS-R high / very high; includes MDS-EB) · Allogeneic hematopoietic cell transplant for high-risk MDS
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | aggressive |
|---|---|
| Linked regimen | REG-ALLOHCT-MDS-HR |
| ID | IND-MDS-HR-ALLOHCT |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-MDS-HR |
| Sources | SRC-ESMO-MDS-2021 SRC-IPSS-M-BERNARD-2022 SRC-NCCN-AML-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track for ALL MDS-HR transplant-eligible. Donor search timing dominates access pathway. Ukraine: limited transplant centers; international referral common.
Used By
Algorithms
ALGO-MDS-HR-2L- ALGO-MDS-HR-2L